MERLIN-TIMI 36

MERLIN-TIMI 36 evaluated a novel anti-ischemic agent, ranolazine, in patients with acute coronary syndromes.

PRESENTATIONS

TIMI 36 Slides
Plasma Omega-6 Fatty Acids & the Risk of CV Events in Patients After Acute ACS in MERLIN (Zelniker AHA 2018)

PUBLICATIONS

Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36

Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial

Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial

Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36

Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial

Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome

Prognostic Performance of Multiple Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Analysis From the MERLIN-TIMI 36 Trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36)

Relation of T-Wave Alternans to Mortality and Nonsustained Ventricular Tachycardia in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome from the MERLIN-TIMI 36 Trial of Ranolazine Versus Placebo

Growth Differentiation Factor-15 Level Predicts Recurrent Cardiovascular Events In Patients With An Acute Coronary Syndrome In MERLIN-TIMI 36

Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36

T-Wave Alternans (TWA) is Associated with Cardiovascular Mortality and NSVTin the MERLIN-TIMI 36 Trial of Ranolazine versus Placebo in Patients with Non-ST Segment Elevation Acute Coronary Syndrome

Low Level Elevation of Highly-Sensitive Cardiac Troponin I after Non-ST Elevation Acute Coronary Syndrome and Early Risk of Cardiac Ischemia and Ventricular Tachycardia: Analysis from MERLIN-TIMI 36

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes

Prognostic Performance Of A Single-Molecule High-Sensitivity Cardiac Troponin Assay After Non-St Elevation Acute Coronary Syndrome: Analysis From MERLIN-TIMI 36

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes

Computationally generated cardiac biomarkers for risk stratification after acute coronary syndrome

Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial

Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial

Myocardial ischemia and ventricular tachycardia on continuous electrocardiographic monitoring and risk of cardiovascular outcomes after non-ST-segment elevation acute coronary syndrome (from the MERLIN-TIMI 36 Trial)

Association of Heart Rate Turbulence, Deceleration Capacity and Morphologic Variability with Sudden Cardiac Death Following Non-ST-Elevation Acute Coronary Syndrome: Results from the MERLIN-TIMI 36 Trial

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial

B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial

Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)

Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome

Metalloproteinase PAPP-A and Outcomes in Patients with ACS: Observations from the MERLIN-TIMI 36 Trial

Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial

Spectral energy of ECG morphologic differences to predict death

Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial

Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial

Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial

Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close